Guardant Health (NASDAQ:GH) Research Coverage Started at Mizuho

Mizuho initiated coverage on shares of Guardant Health (NASDAQ:GH) in a research report released on Thursday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $55.00 price objective on the stock.

Other research analysts have also issued research reports about the company. Stephens reiterated an “overweight” rating and set a $55.00 price target on shares of Guardant Health in a report on Wednesday, March 26th. JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Canaccord Genuity Group increased their price target on shares of Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, February 24th. Piper Sandler lifted their price target on shares of Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Barclays assumed coverage on Guardant Health in a report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price objective on the stock. Twenty investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $49.00.

Guardant Health Stock Up 6.2 %

GH opened at $43.71 on Thursday. The company has a market cap of $5.39 billion, a PE ratio of -12.28 and a beta of 1.45. Guardant Health has a twelve month low of $15.81 and a twelve month high of $50.89. The company has a 50-day moving average price of $43.57 and a 200 day moving average price of $35.69.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. As a group, sell-side analysts expect that Guardant Health will post -2.9 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Norges Bank acquired a new position in Guardant Health during the 4th quarter worth approximately $36,438,000. Two Sigma Advisers LP grew its stake in shares of Guardant Health by 96.7% during the fourth quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock worth $70,742,000 after purchasing an additional 1,138,300 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Guardant Health in the fourth quarter valued at $26,673,000. Lord Abbett & CO. LLC acquired a new stake in Guardant Health in the third quarter valued at $15,624,000. Finally, Two Sigma Investments LP lifted its holdings in Guardant Health by 38.5% during the 4th quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company’s stock worth $57,761,000 after buying an additional 525,368 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.